Transfer of all shares of Jiangsu Kobayashi Pharmaceutical Co., Ltd. to Wantianwan Techan Pharmaceutical (Xiamen) Co., Ltd. The share ownership before and after transfer will be 100% \u2192 0%, with the closing date planned for the end of October 2026. There is a possibility of recognizing extraordinary losses in the fiscal year ending December 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4967","jir_company_name":"Kobayashi Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-08-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4967-20260806-02.pdf","jir_short_summary":"Transfer of all shares of Jiangsu Kobayashi Pharmaceutical Co., Ltd. to Wantianwan Techan Pharmaceutical (Xiamen) Co., Ltd. The share ownership before and after transfer will be 100% \u2192 0%, with the closing date planned for the end of October 2026. There is a possibility of recognizing extraordinary losses in the fiscal year ending December 2026.","jir_summary":"### Overview of the transfer\nKobayashi Pharmaceutical decided by board resolution to transfer all shares of its consolidated subsidiary Jiangsu Kobayashi Pharmaceutical Co., Ltd. to Wantianwan Techan Pharmaceutical (Xiamen) Co., Ltd., with no remaining capital or personnel relationships after the transfer. The transfer agreement is scheduled to be signed in mid-August 2026, with the closing date planned for the end of October 2026.\n\n### Future financial impact and disclosure plan\nAs a result of the transfer, we expect to recognize extraordinary losses in the fiscal year ending December 2026, though the amount is currently under review. We will promptly disclose any new information as it becomes available. Also, the Japanese brand name An-meltsu (\u5b89\u7f8e\u9732) is not manufactured by Jiangsu Kobayashi Pharmaceutical, and the transfer does not affect it.","jir_financial_highlights":"Transfer shareholding ratio: 100% \u2192 0% (0% at the time of transfer)\nTransfer destination capital: 178 million yuan (Capital relationship noted)\nRecognition of extraordinary losses (fiscal year 2026): Unknown (Under review)","jir_category":"","jir_hashtags":"#KobayashiPharmaceutical, #OrganizationalRestructuringAndTransformation","jir_key_figures":"Transfer shareholding ratio: 100% \u2192 0%\nTransfer destination capital: 178 million yuan\nRecognition of extraordinary losses: FY2026 (undetermined)","jir_meta_title":"\u3010Kobayashi Pharmaceutical\u3011Notice of Consolidated Subsidiary Change Due to Share Transfer | August 2026","jir_meta_description":"Kobayashi Pharmaceutical transfers all shares of Jiangsu Kobayashi Pharmaceutical to exit from consolidated subsidiaries. Transfer recipient is Wantianwan Techan Pharmaceutical. Schedule for transfer in fall 2026, with ongoing review of potential extraordinary losses.","jir_og_title":"\u3010Kobayashi Pharmaceutical\u3011Notice of Consolidated Subsidiary Change Due to Share Transfer | August 2026","jir_og_description":"Resolution to transfer all shares of Jiangsu Kobayashi Pharmaceutical. Transfer destination is Wantianwan Techan Pharmaceutical, aiming for completion by late October 2026. Evaluation of potential extraordinary losses is ongoing.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7982,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"corporate_restructuring","footnotes":""},"sector":[],"importance":[],"class_list":["post-97501","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n